Adaptimmune Therapeutics plc (ADAP)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 03:49PM EDT. Market open.
| Previous close | 0.8984 |
| Open | 0.9201 |
| Bid | 0.9369 x 400 |
| Ask | 0.9763 x 300 |
| Day's range | 0.9200 - 1.0800 |
| 52-week range | 0.4200 - 2.0500 |
| Volume | |
| Avg. volume | 2,009,598 |
| Market cap | 248.304M |
| Beta (5Y monthly) | 2.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5400 |
| Earnings date | 04 Mar 2024 - 08 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.50 |
ZacksAdaptimmune (ADAP) Down on End of Collaboration With Roche
Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.
Simply Wall St.Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Adaptimmune Therapeutics ( NASDAQ:ADAP ) Full Year 2023 Results Key Financial Results Revenue: US$60.3m (up 122% from...
GuruFocus.comAdaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results
Key Financial Highlights and Business Updates
© 2024 Yahoo. All rights reserved.